Results 61 to 70 of about 35,905 (251)

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

Advanced Science, EarlyView.
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan, Xuan Liu, Qian‐Fang Meng, Lei Cao, Rongrong Li, Yangtao Xu, Jing Zhang, Chenchen Zhao, Lang Rao, Chen Yu   +9 more
wiley   +1 more source

Shelf-Life Extension of Fc-Fused Single Chain Fragment Variable Antibodies by Lyophilization

Frontiers in Cellular and Infection Microbiology, 2021
Generation of sequence defined antibodies from universal libraries by phage display has been established over the past three decades as a robust method to cope with the increasing market demand in therapy, diagnostics and research.
Kai-Thomas Schneider, Toni Kirmann, Esther Veronika Wenzel, Esther Veronika Wenzel, Jan-Hendrik Grosch, Jan-Hendrik Grosch, Saskia Polten, Doris Meier, Marlies Becker, Paul Matejtschuk, Michael Hust, Giulio Russo, Giulio Russo, Stefan Dübel   +13 more
doaj   +1 more source

Characterization and analysis of scFv-IgG bispecific antibody size variants

mAbs, 2018
Bispecific antibodies are an emergent class of biologics that is of increasing interest for therapeutic applications. In one bispecific antibody format, single-chain variable fragments (scFv) are linked to or inserted in different locations of an intact ...
Mingyan Cao, Chunlei Wang, W. Chung, Dana Motabar, Jihong Wang, Elizabeth Christian, Shihua Lin, A. Hunter, Xiangyang Wang, Dengfeng Liu   +9 more
semanticscholar   +1 more source

Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy

Advanced Science, EarlyView.
By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng, Lei Zheng, Rongkun Tao, Sirui Zheng, Yanke Zhong, Yongxia Niu, Peng Zhang, Xiang Ma, Chen Yang, Min Zhang, Fuyu Duan, Jing Yang, Xuan Wei, Xiang Zhou, Zhenbiao Yang, Zhaoxi Sun, Qizhou Lian   +16 more
wiley   +1 more source

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes

Journal of Nanobiotechnology, 2018
BackgroundRecent advances in nanomedicine have shown the great interest of active targeting associated to nanoparticles. Single chain variable fragments (scFv) of disease-specific antibodies are very promising targeting entities because they are small ...
Christophe Alric, K. Hervé-Aubert, N. Aubrey, Souad Melouk, L. Lajoie, W. Même, S. Même, Y. Courbebaisse, A. Ignatova, A. Feofanov, I. Chourpa, E. Allard-Vannier   +11 more
semanticscholar   +1 more source

Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders

Advanced Science, EarlyView.
Antibody can be engineered into diverse lysosome‐targeting chimeras that convert target recognition into active degradation. By coupling antibody binding with recruited receptors, encoded domains, conjugated ligands, or nanoparticle scaffolds, these antibody‐associated targeted chimeras (AbTACs) platforms direct extracellular and membrane proteins ...
Kaige Chen, Quanyin Hu
wiley   +1 more source

PET Imaging of 64Cu-DOTA-scFv-Anti-PSMA Lipid Nanoparticles (LNPs): Enhanced Tumor Targeting over Anti-PSMA scFv or Untargeted LNPs

Nuclear Medicine and Biology, 2017
Introduction Single chain (scFv) antibodies are ideal targeting ligands due to their modular structure, high antigen specificity and affinity. These monovalent ligands display rapid tumor targeting but have limitations due to their fast urinary clearance.
P. Wong, Lin Li, Junie Chea, M. K. Delgado, Desiree M Crow, E. Poku, B. Szpikowska, Nicole Bowles, D. Channappa, D. Colcher, J. Wong, J. Shively, P. Yazaki   +12 more
semanticscholar   +1 more source

Engineering CAR‐Macrophages With Advanced Delivery Systems for Tissue Repair

Advanced Science, EarlyView.
This review highlights how engineered macrophages equipped with chimeric antigen receptors (CAR) guide tissue repair by recognizing disease‐related targets, clearing harmful cells, and reshaping local immune environments. It summarizes macrophage biology, CAR design, delivery platforms, and functionalization strategies, and discusses emerging ...
Yixin Zhang, Jintian Yu, Liang Yuan, Ziliang Fu, Yiming Yao, Lingna Chen, Shixiong Chen, Aikemu Ainiwaer, Xiaolin Cui   +8 more
wiley   +1 more source

A conjugate of an anti-midkine single-chain variable fragment to doxorubicin inhibits tumor growth

Brazilian Journal of Medical and Biological Research, 2012
Doxorubicin (DOX) was conjugated to a single-chain variable fragment (scFv) against human midkine (MK), and the conjugate (scFv-DOX) was used to target the chemotherapeutic agent to a mouse solid tumor model in which the tumor cells expressed high levels
Shuli Zhao, Guangfeng Zhao, Hao Xie, Yahong Huang, Yayi Hou   +4 more
doaj   +2 more sources

A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints

Advanced Science, EarlyView.
ARESEC is a synthetic platform that reconstructs functional V(D)J recombination in HEK293T cells. By introducing RSS elements and co‐expressing RAG1/2 and TdT across all three antibody CDRs, it enables programmable junctional diversification and direct generation of high‐affinity variants targeting PD‐1/PD‐L1, overcoming the evolutionary constraints of
Wang Liu, Jun Yang, Yuhang Zhang, Xiaoli Xue   +3 more
wiley   +1 more source